Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 2/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804579 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL8348735 | 0.81 | RAF1 (0.58) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL12963488 | 0.79 | RAF1 (0.56) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL12933402 | 0.78 | RAF1 (0.58) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL19687408 | 0.78 | GBA1 (0.46) | RAF1BRAFNPC1RAB9AALDH1A1 | |
| SCHEMBL23321223 | 0.77 | LMNA (0.64) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL19708892 | 0.77 | FPR2 (0.42) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL30353341 | 0.76 | CYP1A2 (0.66) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL913131 | 0.76 | CYP1A2 (0.66) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL28085087 | 0.76 | MAPT (0.63) | CYP1A2CYP2D6MAPTKMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885CYP2D6 1366/4885MAPT 2009/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885CYP2D6 1366/4885MAPT 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.